Aileron Therapeutics Announces Initiation of Expansion Cohort and First Patient Enrolled into Expansion Cohort of Phase 1b/2 Study ...
WATERTOWN, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) announced today the expansion of one of the dose levels in the dose optimization part of its Phase 1b/2 clinical trial evaluating ALRN-6924 as an agent to protect …